These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3417651)

  • 1. Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro.
    Linhardt RJ; Rice KG; Kim YS; Engelken JD; Weiler JM
    J Biol Chem; 1988 Sep; 263(26):13090-6. PubMed ID: 3417651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties.
    Avci FY; Karst NA; Linhardt RJ
    Curr Pharm Des; 2003; 9(28):2323-35. PubMed ID: 14529394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule.
    Maillet F; Petitou M; Choay J; Kazatchkine MD
    Mol Immunol; 1988 Sep; 25(9):917-23. PubMed ID: 3211161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
    Weiler JM; Gleich GJ
    J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase.
    Kazatchkine MD; Fearon DT; Metcalfe DD; Rosenberg RD; Austen KF
    J Clin Invest; 1981 Jan; 67(1):223-8. PubMed ID: 6778897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small heparin fragments regulate the amplification pathway of complement.
    Sharath MD; Merchant ZM; Kim YS; Rice KG; Linhardt RJ; Weiler JM
    Immunopharmacology; 1985 Apr; 9(2):73-80. PubMed ID: 3997506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the formation of the human C-3 amplification convertase of complement by polyelectrolytes.
    Kazatchkine MD; Maillet F; Fischer E; Glotz D
    Agents Actions; 1981 Dec; 11(6-7):645-6. PubMed ID: 6918183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligosaccharide mapping of low molecular weight heparins: structure and activity differences.
    Linhardt RJ; Loganathan D; al-Hakim A; Wang HM; Walenga JM; Hoppensteadt D; Fareed J
    J Med Chem; 1990 Jun; 33(6):1639-45. PubMed ID: 2160537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activation of the alternative pathway C3 convertase by human plasma kallikrein.
    DiScipio RG
    Immunology; 1982 Mar; 45(3):587-95. PubMed ID: 6916710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between the alternative complement pathway and proteases of the coagulation system.
    Kazatchkine MD; Jouvin MH
    Adv Exp Med Biol; 1984; 167():235-9. PubMed ID: 6561912
    [No Abstract]   [Full Text] [Related]  

  • 11. Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin.
    Weiler JM; Yurt RW; Fearon DT; Austen KF
    J Exp Med; 1978 Feb; 147(2):409-21. PubMed ID: 624904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C3 nephritic factor stabilization of the classic C3 convertase: a role for C2 in C3 nephritic factor activity.
    McLean RH; Nilson SH
    Proc Soc Exp Biol Med; 1979 Jul; 161(3):358-63. PubMed ID: 461464
    [No Abstract]   [Full Text] [Related]  

  • 13. Localization of the covalent C3b-binding site on C4b within the complement classical pathway C5 convertase, C4b2a3b.
    Kozono H; Kinoshita T; Kim YU; Takata-Kozono Y; Tsunasawa S; Sakiyama F; Takeda J; Hong K; Inoue K
    J Biol Chem; 1990 Aug; 265(24):14444-9. PubMed ID: 2387864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
    Sturtevant JE; Balber AE
    Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural determinants of the capacity of heparin to inhibit collagen synthesis in 21-day fetal rat calvariae.
    Hurley MM; Kream BE; Raisz LG
    J Bone Miner Res; 1990 Nov; 5(11):1127-33. PubMed ID: 2176772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Trypanosoma cruzi membrane components on the formation of the classical pathway C3 convertase.
    Kipnis TL; Tambourgi DV; Sucupira M; Dias-da-Silva W
    Braz J Med Biol Res; 1986; 19(2):271-8. PubMed ID: 3548858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyions regulate the alternative amplification pathway of complement.
    Weiler JM
    Immunopharmacology; 1983 Oct; 6(3):245-55. PubMed ID: 6629739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
    Parker CJ; Baker PJ; Rosse WF
    J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of RBCs on the activation of human complement by heparin-protamine complexes.
    Shastri KA; Phillips MJ; Raza S; Logue GL; Rustagi PK
    Blood; 1988 Jan; 71(1):36-40. PubMed ID: 3334899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.